Affordable Access

deepdyve-link
Publisher Website

Baseline extent of damage predicts spinal radiographic progression in Korean patients with ankylosing spondylitis treated with golimumab.

Authors
  • Lee, Jeong Seok1
  • Song, Yeong Wook1
  • Kim, Tae Hwan2
  • Chung, Won Tae3
  • Lee, Seung Geun4
  • Park, Sung Hwan5
  • Song, Gwan Gyu6
  • Yu, Dae Young7
  • Xu, Stephen8
  • Lee, Eun Young1
  • 1 Division of Rheumatology, Department of Internal Medicine, Seoul National University Hospital, Seoul, Korea. , (North Korea)
  • 2 Division of Rheumatology, Department of Internal Medicine, Hanyang University Seoul Hospital, Seoul, Korea. , (North Korea)
  • 3 Division of Rheumatology, Department of Internal Medicine, Dong-A University Hospital, Busan, Korea. , (North Korea)
  • 4 Division of Rheumatology, Department of Internal Medicine, Pusan National University Hospital, Busan, Korea. , (North Korea)
  • 5 Division of Rheumatology, Department of Internal Medicine, College of Medicine, Seoul St. Mary's Hospital, The Catholic University of Korea, Seoul, Korea. , (North Korea)
  • 6 Division of Rheumatology, Department of Internal Medicine, Korea University Guro Hospital, Seoul, Korea. , (North Korea)
  • 7 Janssen Korea, Medical Affairs, Seoul, Korea. , (North Korea)
  • 8 Department of Biostatistics, Janssen Research & Development, LLC, Spring House, PA, USA.
Type
Published Article
Journal
The Korean journal of internal medicine
Publication Date
May 01, 2018
Volume
33
Issue
3
Pages
622–628
Identifiers
DOI: 10.3904/kjim.2016.046
PMID: 28103433
Source
Medline
Keywords
Language
English
License
Unknown

Abstract

For patients with ankylosing spondylitis (AS), golimumab has consistent efficacy in controlling disease activity over 5 years but its benefit in preventing radiographic progression was less clear at 4 years. To predict radiographic progression, we analyzed the baseline characteristics of AS patients in a Korean population. Sixty-eight Korean patients with AS participated in the phase 3, multicenter, randomized, placebo-controlled, double-blind trial (GO-RAISE) which has previously been described. Baseline modified stoke AS spine score (mSASSS) and change in mSASSS from baseline (ΔmSASSS) until week 208 were analyzed in the Korean patients enrolled in the GO-RAISE study. Although Korean patients had lower baseline mSASSS compared to non-Korean patients and received active management, radiographic progression was not prevented. Korean patients who did not undergo radiographic progression of spinal lesions of AS were younger and had shorter symptomatic duration, lower Bath AS functional and metrology indices, better chest expansion, and lower baseline mSASSS. The baseline mSASSS and ΔmSASSS were positively correlated in Korean AS patients (p < 0.001). Radiographic progression was more prevalent (80.0%) when baseline mSASSS > 10 and less common (13.0%) with baseline mSASSS = 0. In Korean AS patients, radiographic progression of the spine after 4 years was predicted effectively by the initial severity of the spinal lesion(s) in patients treated with golimumab.

Report this publication

Statistics

Seen <100 times